Evaluation of Safety and Efficacy of DM-28 for Treatment of Moderate to Severe Ocular Dryness

Inclusion Criteria: * Subject with a moderate to severe dry eye syndrome. * Subject with a score ≥ 23 for the OSDI (Ocular Surface Disease Index). * Subject with at least one eye with: * Global ocular staining (cornea and conjunctiva) ≥4 and ≤9 on the Oxford scale (0 to 15) AND one of the following criteria: * Schirmer test ≥ 3 mm/5 min and ≤ 9 mm/5 min OR * Sum of 3 measurements of Tear film Break-Up Time (TBUT) ≤ 30s. * Subject, having given freely and expressly his/her informed consent. * Subject who is able to comply with the study requirements, as defined in the present CIP, at the Investigator's appreciation (investigator expertise). * Subject being affiliated to a health social security system. * Female subjects of childbearing potential should use a medically accepted contraceptive regimen since at least 12 weeks before the beginning of the study, during all the study and at least 1 month after the study end (subject declaration). Exclusion Criteria: * Far best corrected visual acuity (FBCVA) \< 1/10 (according to Snellen Chart) * Subject with severe ocular dryness with one of these conditions (investigator expertise): * Eyelid or blinking malfunction * Corneal disorders not related to dry eye syndrome * Ocular metaplasia * Filamentous keratitis * Corneal neovascularization * Subject with severe meibomian gland dysfunction (MGD) * History of ocular trauma, infection or inflammation, not related to dry eye syndrome within the last 3 months prior to the inclusion * History of ocular allergy or ocular herpes within the last 12 months. * Any troubles of the ocular surface not related to dry eye syndrome. * Subject with hypersensitivity to one of the components of the investigational device. * Subjects who underwent ocular surgery, including laser surgery, in either eye within the last 6 months. * Use of the following systemic or ocular treatments: isotretinoïd, cyclosporine, tacrolimus, sirolimus, pimecrolimus, punctual plugs, corticoids or dry eye therapy (intense pulse light, stem cells) during the month preceding the inclusion. * Subjects who have received ocular therapy (either eye) with any ophthalmic medication, except tear substitutes, within 2 weeks prior to study start or expected to receive ocular therapy during the study. * Any not stabilized systemic treatment, which can have an effect on performance or safety criteria, at the investigator appreciation. * Pregnant or nursing woman or planning a pregnancy during the study (subject declaration/ pregnancy test). * Subject deprived of freedom by administrative or legal decision (subject declaration). * Subject in a social or health institution (subject declaration). * Subject who is under guardianship or who is not able to express his/her consent (subject declaration/ investigator expertise). * Subject being in an exclusion period for a previous study (subject declaration). * Subject suspected to be non-compliant according to the Investigator's judgment (investigator expertise). * Subject wearing contact lenses during the study